Jarislowsky Fraser Ltd lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 753,777 shares of the company’s stock after selling 24,670 shares during the quarter. Jarislowsky Fraser Ltd’s holdings in Johnson & Johnson were worth $133,802,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of JNJ. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after buying an additional 3,358,478 shares during the last quarter. GQG Partners LLC boosted its holdings in shares of Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Johnson & Johnson by 14.0% during the first quarter. Swiss National Bank now owns 11,402,516 shares of the company’s stock worth $2,020,868,000 after purchasing an additional 1,396,500 shares during the last quarter. Finally, Bridgewater Associates LP boosted its holdings in shares of Johnson & Johnson by 40.3% during the first quarter. Bridgewater Associates LP now owns 4,345,002 shares of the company’s stock worth $770,065,000 after purchasing an additional 1,247,260 shares during the last quarter. Institutional investors and hedge funds own 68.59% of the company’s stock.
Johnson & Johnson Trading Down 0.3 %
NYSE:JNJ opened at $166.01 on Wednesday. The business’s 50-day moving average is $164.96 and its two-hundred day moving average is $172.78. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a market capitalization of $436.47 billion, a PE ratio of 24.16, a price-to-earnings-growth ratio of 3.15 and a beta of 0.56.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. During the same period last year, the company posted $2.60 earnings per share. The firm’s revenue was up 1.9% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 9.96 earnings per share for the current fiscal year.
Johnson & Johnson declared that its board has approved a stock repurchase plan on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the company. SVB Leerink decreased their price objective on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Citigroup decreased their price objective on Johnson & Johnson from $201.00 to $198.00 in a report on Wednesday, October 5th. Bank of America decreased their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Morgan Stanley raised their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 12th. Finally, UBS Group cut their target price on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $187.18.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
- This Mid Cap Energy Stock is a 10-Bagger…And May Not Be Done
- Should You Make a Reservation in Marriott International Stock?
- The Outperforming Software Stock No One is Talking About
- Will Goldman Sachs’ Earnings & Revenue Beats Lift Sector Higher?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.